Is PT-141 (Bremelanotide) Legal in Minnesota? How to Access It Legally
HealthRX.com
Vyleesi is the FDA-approved, prescription-only option
Key numbers
- 40.0%Nausea in Vyleesi patients in phase 3 trials, vs 1.3% on placeboSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 45 minutesMinimum wait before sexual activity after a Vyleesi doseSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 6 mmHgMaximum systolic blood pressure rise in Vyleesi clinical studiesSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 8 weeksStop Vyleesi if symptoms do not improve after this longSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 1.75 mgVyleesi dose per subcutaneous autoinjector injectionSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
See the public record for Bremelanotide
At a glance
- Drug / Bremelanotide (also called PT-141); Vyleesi is the approved brand [1]
- FDA approval / June 21, 2019, NDA 210557, now held by Cosette Pharmaceuticals [1][2]
- Approved use / Premenopausal women with acquired, generalized HSDD [1]
- Prescription status / Prescription only, subcutaneous autoinjector [1]
- Compounded PT-141 / Not Vyleesi, not FDA-approved [3]
- Boxed warning and REMS / None [1][2]
What PT-141 is and what FDA approved
Bremelanotide (PT-141) is a cyclic peptide of seven amino acids and a melanocortin receptor agonist. At therapeutic doses the binding that matters most is at MC1R and MC4R, and how it improves desire is unknown [1]. FDA approved it as Vyleesi on June 21, 2019 (NDA 210557); it is now held by Cosette Pharmaceuticals. It is a 1.75 mg subcutaneous injection in a prefilled autoinjector, prescription only [1][2].
The indication is narrow: premenopausal women with acquired, generalized hypoactive sexual desire disorder, meaning low sexual desire causing marked distress or interpersonal difficulty that is not due to a co-existing medical or psychiatric condition, relationship problems, or a medication or drug [1]. The label states it is not indicated for HSDD in postmenopausal women or in men, and not to enhance sexual performance [1].
Vyleesi versus compounded or research-use PT-141
Bremelanotide sold as a compounded or research-use peptide is not Vyleesi and is not an FDA-approved drug. Compounded drugs are not reviewed by FDA for safety, effectiveness or quality before marketing [3][1].
Bremelanotide does not appear on FDA's page of bulk drug substances that may present significant safety risks when compounded, does not appear in any category on FDA's bulk-substance lists, and is not one of the six peptides in HHS's October 2026 draft enforcement-discretion policy [4][5][6].
Key Vyleesi label warnings
The label contraindicates Vyleesi in patients with uncontrolled hypertension or known cardiovascular disease and says it is not recommended in patients at high risk for cardiovascular disease [1]. Each dose transiently raises blood pressure. In clinical studies the maximal increases were 6 mmHg systolic and 3 mmHg diastolic, peaking 2 to 4 hours after the dose, with values usually back to baseline within 12 hours [1]. In an ambulatory study of 127 women dosed daily for 8 days, the mean increases were 1.9 mmHg systolic and 1.7 mmHg diastolic [1].
The label says to avoid Vyleesi with oral naltrexone-containing products intended to treat alcohol or opioid addiction, because Vyleesi may significantly decrease oral naltrexone exposure. It also says to use effective contraception and to stop Vyleesi if pregnancy is suspected [1]. In the phase 3 trials, nausea occurred in 40.0% of Vyleesi patients versus 1.3% on placebo; 13% needed an anti-nausea medicine and 8% discontinued the trials because of it [1].
How Vyleesi is used
The labeled regimen is 1.75 mg injected under the skin of the abdomen or thigh as needed, at least 45 minutes before anticipated sexual activity [1]. The label says not to use more than one dose in 24 hours and does not recommend more than eight doses a month. It also says to stop after 8 weeks if there is no improvement in symptoms [1].
Minnesota requirements
Vyleesi is a prescription-only drug under its FDA label [1]. That status comes from FDA and does not tell us what Minnesota's own statutes, pharmacy rules or telehealth prescribing standards add, and this page does not address them.
Check what you know
Question 1 of 4
Score: 0 right, 0 of 4 answered
Questions worth asking
Frequently asked questions
Is PT-141 the same as Vyleesi?
Is compounded PT-141 FDA-approved?
Can Vyleesi be prescribed for men or postmenopausal women?
Does Vyleesi have a boxed warning or a REMS?
Reader questions
What people actually ask
Short answers drawn from the sources this article cites.
Where can I get PT-141?
Vyleesi is the FDA-approved, prescription-only form of bremelanotide, given as a 1.75 mg subcutaneous autoinjector. Products sold as compounded or research-use PT-141 are not Vyleesi and are not FDA-approved drugs. FDA's prescription-only status does not settle what additional Minnesota rules apply.
Where can I buy PT-141 nasal spray online?
Vyleesi is not a nasal spray. Its label describes a subcutaneous injection in a prefilled autoinjector, given as 1.75 mg under the skin of the abdomen or thigh. Compounded or research-use PT-141 sold online is not Vyleesi and is not FDA-approved, and compounded drugs are not reviewed by FDA for safety, effectiveness or quality before marketing.
References
Show all 7 referencesHide references
- U.S. National Library of Medicine, DailyMed. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector prescribing information. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector label
- U.S. Food and Drug Administration. Approval letter, NDA 210557, 2019. FDA approval letter, NDA 210557
- Federal Register public inspection document 2026-22192. Federal Register document 2026-22192
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- U.S. Food and Drug Administration. Bulk drug substances lists. FDA bulk drug substances lists
- U.S. Department of Health and Human Services. Peptide enforcement discretion policy, Appendix B. HHS peptide enforcement discretion policy, Appendix B
- Understanding Unapproved Use of Approved Drugs "Off Label" | FDA.